Skip to main content

Diplomatic Trade Ltd, Thomas J. Kent Jr. the Kent Family Office, and Kent Global LLC Stake Acquisition in Turkish Pharma Firm, Target $300M UAE Biopharma Venture

Written by Customer Service on . Posted in Mergers And Acquisitions.

Cross-border biopharma venture targets $300M IPO valuation and UAE facility launch by Q3 2025

Thomas J. Kent Jr.

Thomas J. Kent Jr.

DUBAI, United Arab Emirates, July 31, 2025 (GLOBE NEWSWIRE) — Diplomatic Trade Ltd and Kent Global Support Strategic Stake in Turkish Pharma Group, Plan $300M UAE Biopharma Initiative Cross-border biopharma venture targets UAE facility launch in Q3 2025 and public listing by year-end

Diplomatic Trade Ltd, a cross-border trade and investment firm with offices in New York and Dubai, and its private equity arm, Diplomatic Trade Capital Group, have signed an MOU to acquire a 49% stake in Turkish pharmaceutical manufacturer Farmakim ilaç Kimya Gida Ürünleri Üretim San ve Dis Tie A.S.

The transaction was supported by U.S.-based Kent Family Office LLC and its affiliated investment firm, Kent Global LLC, led by financier Thomas J. Kent Jr. The deal marks a strategic partnership aimed at strengthening pharmaceutical capacity across Türkiye and the Gulf Cooperation Council (GCC).

Equity Position and Strategy
Diplomatic Trade Capital’s 49% ownership includes board representation and commercial rights. Financial details were not disclosed, but the acquisition aligns with a broader strategy to scale pharmaceutical infrastructure across emerging markets in MENA.

UAE Biomanufacturing Facility – Q3 2025
The partners will establish a UAE-based biomanufacturing facility by Q3 2025. The plant will focus on biosynthetic therapies and regenerative compounds, featuring modular, EU-GMP-compliant production systems and AI-driven quality control. The facility is intended to meet growing demand for advanced pharmaceuticals in the GCC and North Africa.

IPO Planning and Market Valuation
The new entity is targeting an initial public offering on a UAE stock exchange in Q4 2025. A global advisory firm is conducting a valuation, with early estimates suggesting a potential IPO valuation near $300 million USD, based on projected revenue growth and regional distribution rights.

Institutional Investment Backing
The financing structure was arranged by Kent Family Office and Kent Global, reflecting increased U.S. institutional interest in healthcare investment across the Gulf region.

Executive Commentary
“This transaction establishes a platform for scalable pharmaceutical production in the region,” said a Diplomatic Trade Capital spokesperson. “The UAE offers a favorable environment for innovation, regulation, and capital markets access.”

About Diplomatic Trade Ltd
Diplomatic Trade Ltd is a U.S.-registered firm focused on cross-border joint ventures and IPOs in healthcare, infrastructure, and strategic manufacturing across the GCC and Africa.

About Farmakim
Based in Istanbul, Farmakim is a privately held pharmaceutical company serving public and private healthcare systems across Europe, MENA, and Central Asia.

Media Contact:
Shawn Kent
Kent Global LLC and The Kent Family Office
646 207 6801
tkent@kentgloballlc.net
https://www.kentgloballlc.net/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6ca9a779-f567-40ae-9944-7f2d25ebde78

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.